<DOC>
	<DOCNO>NCT00002415</DOCNO>
	<brief_summary>The purpose study see safe effective add PMPA Prodrug ( new anti-HIV drug ) anti-HIV drug combination take patient take anti-HIV drug past . Genetic response study .</brief_summary>
	<brief_title>Safety Effectiveness Adding PMPA Prodrug Anti-HIV Drug Combination Treat HIV-Infected Patients</brief_title>
	<detailed_description>Prior study entry patient stratify accord HIV-1 RNA level , CD4 cell count , number antiretroviral drug . PMPA Prodrug placebo add current antiretroviral regimen , administer one three dose regimen . Patients randomize receive placebo eligible receive open-label PMPA Prodrug remainder 48-week study period least 24 week post randomization .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive . Have HIV count 400 50,000 copies/ml . Are expected live least 1 year . Have take antiHIV drug combination ( make 3 antiHIV drug ) least 8 week prior study entry . Are least 18 year old . Agree use effective method birth control study . Exclusion Criteria You eligible study : Have take medication certain infection within 15 day prior study entry . Have history cancer , except Kaposi 's sarcoma ( KS ) skin cancer . Develop new AIDSrelated condition within 30 day study entry . Have certain serious medical condition , include severe nausea , vomit , stomach problem make unable take medication mouth . Have receive vaccine within 30 day prior study entry . Have take certain medication , include may affect kidney . Abuse alcohol drug . Are pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 1999</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Prodrugs</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>